Botulinum toxin product study results released

Santa Barbara, Calif. - Inamed Corporation and its partner Ipsen,a European pharmaceutical company, reported results of a Phase II dosingstudy of their botulinum toxin type A product yesterday at the AAD meeting.

Related Videos
Related Content

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023

HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52

February 3rd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Losing a Malpractice Case May Depend on Where You Live

February 3rd 2023

The Cutaneous Connection: An Inside Look of the Inclusive Atlas

November 4th 2021

The Role We Play in Addressing Racial Disparity in Dermatology

February 2nd 2023

The Mainstream Patient: February 2

February 2nd 2023
Advertise
Contact Us
Job Board
Do Not Sell My Information
Terms and Conditions
Privacy Policy
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.